Advanced Solid Tumors Study
If you or a loved one has suffered from advanced solid tumors, a clinical study may be able to help.
The study has 2 Phases, a dose escalation phase and dose expansion phase. The goal of the first part of the study is to determine the safety and side effects of PBI-410 and to determine the best dose(s) to be used in the future.The goal of Phase 2 is to test if PBI-410 is effective in treating specific types of cancers.
Length of Study
# Study Visits
Post-study Follow Up
Who’s Included?
Adults; All genders
18–85
Drug & Formulation
PBI-410
Infusion
Possibility of Placebo
Many cancer cells have a higher amount of a certain protein, called “Trop-2”, than normal cells. PBI-410 is a drug that has been designed with a Trop-2 antibody that is connected to an anti-cancer drug. These types of therapies are called antibody-drug conjugates (ADC). The antibody is expected to allow PBI-410 to attach to the Trop-2 protein on cancer cells, so that the anti-cancer drug can move into the cancer cells and kill them.
- Locally advanced or metastatic epithelial solid tumor that cannot be removed with surgery, is incurable and did not respond to standard therapies, or there are no approved standard therapies, or no approved standard therapies at its current treatment stage.
- Participant is a woman who is pregnant or lactating.
- Participant has symptomatic brain metastases.
- Participant has corneal disease.
- Participant requires supplemental oxygen for daily activities.
- Participant had previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
- Participant had or has interstitial lung disease.
Learn more about the benefits of joining our trial and see if you qualify today!
Frequently Asked Questions
About 410 people will participate in this study.
The study is being conducted on behalf of Biohaven .
Visit the See If You Qualify page if you are interested in participating in this study.